Annex Z

Details of AstraZeneca Allocation Process

Because Emergency Use Listing (EUL) has yet to be granted by WHO in respect of this vaccine, we have for now only provided an indicative number of doses, covering the next two quarters. We would like to underscore that the indicative distribution is based on current communication of estimated availability from manufacturers. In this regard, it is likely the distribution may need to be adjusted in light of circumstances that are difficult to anticipate and variables that constantly evolving. Therefore, please keep this in mind when considering the estimated indicative allocated quantities.

Please also note that due to this vaccine being supplied from two different manufacturers, namely Serum Institute of India (SII) and SK Bioscience (SKBio), additional registration or waiver requirements may transpire.

Caveats

In order for you to understand the indicative allocation of this vaccine, please consider the following:

- This indicative allocation does not imply or pre-suppose that this vaccine will be granted WHO's EUL;
- The actual allocation will only be triggered once this product is granted the WHO EUL;
- The supply volume may vary due to manufacturing constraints, and this will have an impact on the doses that will be allocated to Participants;
- No doses will be allocated if a participant is deemed not ready (for AMC Participants), causing variations in the quantities allocated to the other participants;
- The exact delivery after allocation will depend on the sequence of Participants for the shipment plan, the time taken to place the purchase order, legal / regulatory obligations, as well as the supplier's lead time and related logistics;
- If during this period different products become available, this indicative allocation will need to be adjusted as different products may be allocated to your economy and therefore the quantities indicated for the AstraZeneca AZD1222 vaccine may be altered.